Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 20, 2025

Primary Completion Date

October 20, 2026

Study Completion Date

October 20, 2028

Conditions

Head &Amp; Neck Squamous Cell Carcinoma

Interventions

DRUG

Tislelizumab Combined With Chemotherapy for 4 cycles

Tislelizumab: 200mg, day 1, every 3 weeks for 4 cycles Cisplatin: 75mg/m\^2 Nab-paclitaxel: 260mg/m\^2

DRUG

Tislelizumab Combined With Chemotherapy for 2 cycles

Tislelizumab: 200mg, day 1, every 3 weeks for 2 cycles Cisplatin: 75mg/m\^2 Nab-paclitaxel: 260mg/m\^2

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER